

Shield Therapeutics plc
("Shield" or the "Group" or the "Company")

Results of 2021 Annual General Meeting

London, UK, 17 June 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru[®]/Accrufer[®] (ferric maltol), announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2021. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below.

The following table shows the votes cast on each resolution:

	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
Resolution 1	115,096,905	99.94	6,544	0.01	883,488
Resolution 2	115,083,904	99.2	866,271	0.75	36,762
Resolution 3	115,083,904	99.2	866,271	0.75	36,762
Resolution 4	115,927,366	99.93	25,810	0.02	36,761
Resolution 5	115,086,905	99.2	866,271	0.75	36,761
Resolution 6	115,082,443	99.2	867,732	0.75	36,762
Resolution 7	115,083,904	99.2	866,271	0.75	36,762
Resolution 8	115,114,781	99.2	866,695	0.75	5,461
Resolution 9	115,956,508	99.93	27,207	0.02	3,222
Resolution 10	115,905,527	99.91	47,834	0.04	33,576
Resolution 11	115,719,269	99.75	228,432	0.2	39,236
Resolution 12	114,882,135	99.03	1,065,566	0.92	39,236

Notes:

1. Number of shares in issue 215,837,965.
2. Details of the votes received on the resolutions are available on the Company's website: <https://www.shieldtherapeutics.com/corporate-documents/>.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

For further information please contact:

Shield Therapeutics plc

Greg Madison, CEO
Lucy Huntington-Bailey (General Counsel and
Company Secretary)

www.shieldtherapeutics.com

+44 (0)19 1511 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/Matt Radley/Alice Lane

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780 or shield@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru[®] /Accrufer[®] (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru[®]/Accrufer[®], has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer[®] in the US during 2021 through a highly experienced sales and marketing team. Feraccru[®] is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru[®]/Accrufer[®] in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx